Multiple myeloma is the second most common hematologic malignancy, with approximately 15,000 new cases each year in the United States. Our understanding of the pathophysiology underlying myeloma continues to expand, but the cause of this plasma cell dyscrasia remains unclear. Though controversy remains regarding a possible viral cause of myeloma, evidence suggesting a role for the human herpesvirus-8 is mounting. The roles of cytogenetic abnormalities as well as aberrant angiogenesis and cytokine expression in the etiology of myeloma continue to be explored and may lead to future therapeutic strategies. Transplantation in myeloma is rarely curative but offers clinical benefit not only for young but possibly for older myeloma patients as well. Newer bisphosphonates may offer greater ease of administration, improved efficacy, and possibly even enhanced antitumor effect. Finally, thalidomide offers significant clinical benefit to patients with myeloma previously refractory to multiple agents, and its role in early stages of the disease is under investigation.
Multiple myeloma accounts for approximately one tenth of all hematologic malignancies, and its incidence is rising with the aging of our society. Though we continue to add to our understanding of the pathophysiology underlying myeloma, the cause of this plasma cell dyscrasia remains unclear. Though controversy remains regarding a possible viral cause of myeloma, evidence suggesting a role for human herpesvirus-8 (HHV-8) is mounting. The roles of cytogenetic abnormalities as well as aberrant angiogenesis and cytokine expression in the development of myeloma are better understood and may lead to the development of novel therapeutic strategies. Clearly novel therapeutic approaches are needed because the median survival of patients with myeloma remains approximately 3 years. Transplantation in myeloma is rarely curative but offers clinical benefit not only for young but possibly for older myeloma patients as well. Bisphosphonates have become part of the standard of care for bone disease and hypercalcemia in myeloma, but newer analogues may offer greater ease of administration, improved efficacy, and possibly even enhanced antitumor effect. Finally, thalidomide offers significant clinical benefit to patients with myeloma previously refractory to multiple agents, and its role in early stages of the disease is under investigation.
Human herpesvirus-8
Kaposi's sarcoma-associated herpesvirus, also known as HHV-8, is a member of the gamma herpesvirus family. HHV-8 was recently detected in the majority of bone marrow stromal cell cultures from myeloma patients and in a subset of cultures derived from patients with monoclonal gammopathy of undetermined significance (MGUS), yet it is found only rarely in normal individuals [1] . In situ hybridization demonstrated that the virus was not within the plasma cell but instead within the supporting dendritic cells in the bone marrow microenvironment [2]. Although some groups have failed to corroborate these findings [3, 4] , others have found similar evidence of HHV-8 in myeloma patient material [5] [6] [7] [8] . Whether this viral infection is an epiphenomenon or is important in myeloma pathogenesis remains uncertain. Our recent finding that the strain of HHV-8 present within myeloma patients may be restricted and may differ from that found in patients with Kaposi's sarcoma suggests the importance of HHV-8 in these patients' malignancy [9] . The observation that patients with active myeloma are more likely to exhibit HHV-8 infection than patients with inactive disease [10] also argues against a mere epiphenomenon.
Early serologic studies failed to detect HHV-8 expression in myeloma patients [11] , but recent studies successfully identified antibodies against HHV-8 in myeloma patients using a more sensitive technique [12] . The difficulty in documenting serologic evidence of HHV-8 in myeloma patients may reflect the relative immunodeficient state typically associated with the disease or may indicate a specific immune defect preventing the generation of a serologic response to HHV-8. Alternatively, if a myelomaspecific HHV-8 strain exists, as our data suggest, this virus may have a different immunogenic profile compared with the HHV-8 strains commonly found in Kaposi's sarcoma.
Cytogenetics
There is growing evidence that rearrangement, alteration, or amplification of cellular oncogenes leads to human malignancy. Moreover, these changes are often correlated with specific chromosomal abnormalities at the oncogenic sites. Though numerous structural and numerical abnormalities are typically found in myeloma cells, myeloma-specific cytogenetic abnormalities have not been identified. The study of cytogenetic abnormalities in myeloma has been hampered by the low proliferative rate of its malignant cells. Consequently, conventional cytogenetics, which requires cells in metaphase, is often unrewarding and underestimates the prevalence of existing genetic abnormalities. The identification of karyotypic abnormalities in myeloma has recently improved significantly with the development of fluorescence in situ hybridization (FISH) and spectral karyotypic imaging studies. These techniques are capable of more discretely identifying existing abnormalities within malignant cells and may allow subclassification of myeloma patients.
Virtually 100% of myeloma patients have chromosomal abnormalities in their plasma cells based on FISH [13, 14] . FISH studies have demonstrated that 60% to 75% of myeloma patients have an illegitimate rearrangement involving the immunoglobulin heavy-chain gene at 14q32 [15•,16]. Loss of chromosome 13 has been associated with a poor prognosis in myeloma [14, 17] . Cytogenetic studies showed a significantly lower incidence of monosomy 13 in MGUS compared with myeloma and a significantly higher incidence of this deletion in post-MGUS myeloma compared with de novo myeloma [18]. These observations suggest that this chromosomal alteration may confer a growth or survival advantage to the malignant plasma cell and may be involved in the transformation of MGUS to myeloma. Ultimately, targeted therapeutics based on the genetic abnormalities within a patient's tumor clone may become possible, as was recently demonstrated for patients with chronic myeloid leukemia. However, presently we cannot recommend routine cytogenetic analysis of all myeloma bone marrow aspirates because the knowledge of adverse prognosis does not lead to a change in the treatment approach for a given patient.
Angiogenesis
Although the importance of angiogenesis in solid tumors is well established, its role in hematopoietic malignancies such as myeloma is still under exploration. Recent studies report a significant increase in bone marrow microvessel density in patients with active myeloma compared with patients with inactive myeloma, MGUS patients, and normal subjects [19] [20] [21] . A recent abstract reported that a low level of angiogenesis is a major favorable prognostic variable for both event-free survival as well as overall survival on multivariate analysis in myeloma patients [22] . The increased angiogenesis found in myeloma persists after autologous peripheral stem cell transplantation even in patients who achieve a complete response [23] , and this change may contribute to posttransplant relapse. Potential angiogenic factors mediating this increase in angiogenesis include basic fibroblast growth factor [19] and vascular endothelial growth factor [20]. Interestingly, thalidomide may exert some of its beneficial effect in myeloma by its inhibition of angiogenesis.
Growth factors
Interleukin-6 has been shown to function as the primary growth factor for myeloma and reportedly functions as both an autocrine and paracrine factor [24] . This cytokine appears to protect plasma cells from undergoing chemotherapy-induced apoptosis [25, 26] , and patients treated with anti-interleukin-6 monoclonal antibodies respond to treatment, although presently this approach is limited by the development of neutralizing human antimouse antibodies [27] .
Interleukin-1β is a potent bone resorption factor and can be produced by myeloma cells directly [28, 29] . By using in situ hybridization, interleukin-1β secretion was found to be increased in bone marrow aspirates derived from patients with MGUS and myeloma when compared with normal subjects [30, 31] . Patients with lytic bone lesions were more likely to have elevated interleukin-1β transcripts. This factor can also induce interleukin-6 stromal cell production and thus can serve as a mediator of paracrine-induced myeloma cell growth [29] .
Tumor necrosis factor-α has been found to protect myeloma cells from interleukin-6-deprived apoptosis and can induce the growth of some myeloma cell lines [29, 32] . Tumor necrosis factor-α serum levels are often increased in patients with MGUS, and increased levels may be predictive of transformation from MGUS to myeloma [33,34].
Insulin-like growth factor also appears to have a stimulatory role in myeloma cell growth [35, 36] . This factor may increase the sensitivity of plasma cells to interleukin-6 [37] and inhibit dexamethasone-induced apoptosis [38] . Recent studies also suggest that insulin-like growth factor may serve as a homing factor for plasma cells and may mediate plasma cell chemotaxis to the bone marrow [39] .
Interleukin-10 is a critical cytokine involved in the terminal differentiation of B cells into plasma cells. It also appears to function as a growth factor of malignant plasma cells and is produced by myeloma cells from about half the myeloma patients examined [40] . The myeloma cell growth promoting activity of interleukin-10 may be mediated through the cytokine oncostatin M, a glycoprotein-130 interleukin-6 transducer frequently produced by myeloma cells [40] .
Myeloma is associated with unbalanced bone remodeling causing lytic bone lesions. Hepatocyte growth factor is emerging as a possible factor involved in myeloma bone disease by its ability to induce interleukin-11 production from osteoblasts [41,42•]. Interleukin-11 promotes osteoclast formation [43] and inhibits osteoblast activity [44] and may thus be one factor involved in cancer-induced bone destruction. Transforming growth factor-1β and interleukin-1 potentiate hepatocyte growth factor-induced interleukin-11 secretion, whereas an additive effect was observed with tumor necrosis factor [42•].
Therapy for initial disease
Patients with symptomatic myeloma should be treated as soon as the diagnosis is established. Because myeloma is an incurable disease with standard chemotherapy except in rare cases [45] , this treatment is generally given for palliative purposes only. Despite the rarity of cure, however, responses to chemotherapy are high (50% to 75%), and treated patients have median survival times of 24 to 40 months compared with less than 12 months for untreated patients. Patients with asymptomatic and indolent disease do not require immediate therapy because there is no difference in survival in patients treated at diagnosis versus those treated at time of disease progression [46] .
Many oncologists consider the combination of melphalan and prednisone optimal therapy, especially for the elderly and for patients with minimal disease. Several attempts have been made to improve on the response rate and the overall survival benefit seen with melphalan-prednisone therapy. Unfortunately, a recent metaanalysis of 27 trials that randomly allocated more than 6500 patients with myeloma between combination chemotherapy and melphalan-prednisone failed to demonstrate a significant survival advantage between the groups [47••]. Monotherapy with high-dose steroids also provides clinical response rates and improvement in overall survival similar to more aggressive combination chemotherapy regimens [48] . The addition of interferon-α to melphalan-prednisone therapy has been shown to improve response rates for myeloma patients, but at considerable expense and morbidity that does not translate into a meaningful prolongation in overall survival [49] .
High dose chemotherapy
Because myeloma is sensitive to cytotoxic agents in most patients, dose-intensive chemotherapy with marrow transplantation has been evaluated in an attempt to induce complete remission and to improve disease-free survival. Initial trials focused on the use of allogeneic bone marrow transplantation in myeloma. Unfortunately, allogeneic transplantation is associated with a 40% to 50% treatment-related mortality [50,51•] and is therefore a viable option only for myeloma patients less than 55 years of age who have an HLAidentical sibling. As myeloma is a disease of the elderly, fewer than 5% of all patients are eligible for this procedure. If treatment-related mortality can be improved on by the use of nonmyeloablative regimens currently undergoing clinical trials [52] , this procedure may become more acceptable, especially considering its potential for achieving long-term survival with reduced toxicity.
For the few patients with an available identical twin, syngeneic transplantation in multiple myeloma appears to be the treatment of choice. Syngeneic transplantation was recently shown to confer a significantly better median overall survival time in myeloma patients compared with matching myeloma patients receiving autologous or allogeneic transplants [53] . Progression-free survival time was also prolonged and was comparable to that obtained for myeloma patients following allogeneic transplantation who survive the initial treatment.
Myeloablative chemotherapy with autologous transplantation is now widely performed for patients with myeloma and has become part of the standard of care for patients with advanced disease who are less than 65 years of age. Several clinical trials have demonstrated the benefit of autologous transplantation in multiple myeloma [54] [55] [56] [57] . Interestingly, it appears that the benefits of autologous transplantation are similar in patients receiving this procedure at presentation (following some initial chemotherapy) or at the time of first relapse [58] . However, though overall survival was similar between both groups, the quality of life was judged better for patients who received early high-dose chemotherapy, likely caused by the additional chemotherapy needed to reattain remission following the development of progressive disease. Elderly patients may benefit from this more aggressive approach as well, but they tend to have slightly higher treatment-related mortality and more prolonged recovery times that may adversely affect quality of life [57, 59] .
Unfortunately, the majority of myeloma patients undergoing high-dose chemotherapy continue to relapse within 4 years, with median survival times between 36 and 65 months [60] [61] [62] . To improve on these results, attempts have been made to eliminate contaminating tumor cells from the reinfused autograft. However, despite significant reductions in the tumor burden of the autografts, no improvement in progression-free or overall survival has been demonstrated to date [63, 64] .
Maintenance therapy
Studies have shown that continued chemotherapy in patients who have achieved a stable remission offers no advantage in terms of duration of remission or survival. However, a recently completed Southwestern Oncology Group study reported in abstract form suggests that maintenance therapy with either 10 or 50 mg of prednisone every other day improves both progression-free survival as well as median overall survival time [65•]. This study suggests that all responding patients should be treated with prednisone maintenance therapy to prolong the duration of remission.
Therapy for refractory myeloma
Patients who have relapses during therapy or within 6 months of stopping maintenance and patients with primary resistant disease have a poor prognosis. Those without evidence of progressive disease should be watched closely without therapy. Symptomatic patients may benefit from salvage therapy using oral thalidomide. A recent phase II trial demonstrated that 32% of patients with myeloma refractory to numerous salvage regimens could achieve a response [66••] . Because thalidomide causes only mild cytopenias, it is also beneficial for patients who have relapses following high-dose chemotherapy because bone marrow reserve may be limited in these patients. Side effects are frequent and commonly consist of sedation, constipation, and neuropathy. Thalidomide doses as low as 50 mg/d also appear to be effective [67] . A recent abstract suggests that the combination of steroids and thalidomide is particularly active [68] .
Bone disease
The severe bone pain commonly experienced by myeloma patients is successfully alleviated by palliative radiotherapy in most cases. However, this modality should be used only sparingly because the irradiation of large areas of hematopoietically active bone marrow can make future chemotherapy intolerable or high-dose chemotherapy impossible. Intravenous pamidronate has been demonstrated in randomized trials to reduce the skeletal complications that occur in myeloma patients and to improve patients' quality of life [69, 70] . Recent trials with the more potent bisphosphonates ibandronate and zoledronic acid have been published in abstract form. Ibandronate failed to reduce the incidence of skeletal complications in myeloma patients [71] , despite its documented efficacy in vivo in a myeloma mouse model [72] . This poor result may be due to inadequate study drug dose because higher doses of oral ibandronate (50 mg instead of 2 mg) were not only well tolerated but also reduced the rate of bone resorption in myeloma patients in a recent phase I/II trial [73] . Zoledronic acid appeared more effective at controlling hypercalcemia compared with pamidronate in a recently completed phase II study [74] . In vitro studies suggest that bisphosphonates may possess direct antitumor properties [75] . This finding may explain the prolonged survival seen in myeloma patients on salvage chemotherapy treated with intravenous pamidronate compared with patients receiving placebo in the randomized study [69] .
Conclusions
The past year has seen major advances in our knowledge of the pathophysiology underlying multiple myeloma. However, despite these advances patient survival remains largely unaffected. It is hoped that continued progress in our understanding of this disease will eventually lead to more targeted, well-tolerated therapeutic interventions with a more significant impact on patient survival.
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